KR100210698B1 - 간실질 세포 증식제 - Google Patents

간실질 세포 증식제 Download PDF

Info

Publication number
KR100210698B1
KR100210698B1 KR1019920009515A KR920009515A KR100210698B1 KR 100210698 B1 KR100210698 B1 KR 100210698B1 KR 1019920009515 A KR1019920009515 A KR 1019920009515A KR 920009515 A KR920009515 A KR 920009515A KR 100210698 B1 KR100210698 B1 KR 100210698B1
Authority
KR
South Korea
Prior art keywords
hhgf
heparin
hepatic parenchymal
parenchymal cell
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920009515A
Other languages
English (en)
Korean (ko)
Other versions
KR930000120A (ko
Inventor
다이지 나까
Original Assignee
미우라 아끼라
미쓰비시 가가꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미우라 아끼라, 미쓰비시 가가꾸 가부시키가이샤 filed Critical 미우라 아끼라
Publication of KR930000120A publication Critical patent/KR930000120A/ko
Application granted granted Critical
Publication of KR100210698B1 publication Critical patent/KR100210698B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Medical Uses (AREA)
KR1019920009515A 1991-06-03 1992-06-02 간실질 세포 증식제 Expired - Fee Related KR100210698B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP13127191 1991-06-03
JP91-131271 1991-06-03
JP3812292 1992-02-25
JP92-38122 1992-02-25

Publications (2)

Publication Number Publication Date
KR930000120A KR930000120A (ko) 1993-01-15
KR100210698B1 true KR100210698B1 (ko) 1999-07-15

Family

ID=26377318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920009515A Expired - Fee Related KR100210698B1 (ko) 1991-06-03 1992-06-02 간실질 세포 증식제

Country Status (9)

Country Link
US (2) US5545722A (enExample)
EP (1) EP0517182B1 (enExample)
KR (1) KR100210698B1 (enExample)
AT (1) ATE143810T1 (enExample)
CA (1) CA2070263A1 (enExample)
DE (1) DE69214355T2 (enExample)
ES (1) ES2094848T3 (enExample)
HU (1) HUT62315A (enExample)
TW (1) TW318142B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
GB9306255D0 (en) * 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
EP0730466A4 (en) * 1993-09-10 1999-04-14 Univ New York COMPOSITIONS AND METHOD FOR INHIBITING THE INVASION OF HEPATOCYTES BY MALARIASPOROZOITES
US6756358B2 (en) 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU7389496A (en) * 1995-10-05 1997-04-28 Genentech Inc. Methods and compositions for treating vascular stenosis
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
WO2000024416A1 (en) * 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
US7829072B2 (en) * 2000-07-14 2010-11-09 Carter Daniel C Serum albumin compositions for use in cleansing or dermatological products for skin or hair
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
SE525461C3 (sv) 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
WO2005055949A2 (en) * 2003-12-09 2005-06-23 The Children's Hospital Of Philadelphia Sustained release preparations composed of biocompatible complex microparticles
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
EP0412577A1 (de) * 1986-05-09 1991-02-13 Hoechst Aktiengesellschaft Herbizide Mittel
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物
JPH0247916A (ja) * 1988-08-08 1990-02-16 Nec Corp アナログコンパレータ
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd

Also Published As

Publication number Publication date
CA2070263A1 (en) 1992-12-04
US5736506A (en) 1998-04-07
TW318142B (enExample) 1997-10-21
ES2094848T3 (es) 1997-02-01
HU9201856D0 (en) 1992-08-28
HUT62315A (en) 1993-04-28
EP0517182B1 (en) 1996-10-09
DE69214355D1 (de) 1996-11-14
ATE143810T1 (de) 1996-10-15
KR930000120A (ko) 1993-01-15
DE69214355T2 (de) 1997-03-06
US5545722A (en) 1996-08-13
EP0517182A1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
Meyer et al. Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors
Gabbiani et al. Reparative processes in mammalian wound healing: the role of contractile phenomena
US5736506A (en) Method of inhibiting the degradation of hepatocyte growth factor
Smith et al. Interleukin-8 induces neutrophil transendothelial migration
Kanwar et al. Partial characterization of newly synthesized proteoglycans isolated from the glomerular basement membrane.
US8329870B2 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
ES2149776T5 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
KR102006036B1 (ko) 히알루론산-결합 합성 펩티도글리칸 및 이의 제조 및 이용 방법
Mueller et al. Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro
JP3973050B2 (ja) モルフォゲン誘発性肝再生
JPH09502440A (ja) ヘパリン結合の阻害
BR112012031587B1 (pt) Composição compreendendo um peptídeo e pelo menos um outro componente farmaceuticamente aceitável para o tratamento ou prevenção de dano de cartilagem e artrite
EP0456188A1 (en) Therapeutic agent for hepatocirrhosis
CA2361612A1 (en) Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans
EP3617222A1 (en) Peptide for inducing regeneration of tissue, and use thereof
D'Amore Heparin-endothelial cell interactions
WO1993008821A1 (fr) Inhibiteur des effets secondaires dans la therapie du cancer
KR19990066997A (ko) 조혈성 간세포의 이동 방법
JP2002512018A (ja) マトリックス結合因子
JP3305355B2 (ja) 肝実質細胞増殖剤
West et al. A specificity for cellular fibronectin in its effect on cultured chondroblasts
CA2005154A1 (en) Method for purifying fibroblast growth factor protein
JP3030386B2 (ja) 抗ガン剤
Hallén et al. Hyaluronan localization in the rabbit larynx
Ponzin et al. Characterization of macrophages elicited by intraperitoneal injection of hyaluronate

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20030402

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040429

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040429

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000